International Edition
Latest News
Health

Novel TB Regimens Show Promise in Phase II Platform Trial

Two investigational four-drug regimens for tuberculosis showed higher probabilities of superiority compared with standard therapy in a phase II platform trial published on Thursday in the New England Journal of Medicine. The trial evaluated multi-drug combinations designed to…

Two investigational four-drug regimens for tuberculosis showed higher probabilities of superiority compared with standard therapy in a phase II platform trial published on Thursday in the New England Journal of Medicine.

The trial evaluated multi-drug combinations designed to shorten treatment duration for rifampin-susceptible pulmonary tuberculosis. Tuberculosis causes more than 1 million deaths globally each year, making the development of shorter therapies a priority for public health agencies seeking disease elimination.

The PARADIGM-4TB trial assigned 401 adult participants across 14 clinical sites in South Africa, Tanzania, Uganda, Vietnam, and Moldova to receive either standard therapy or one of several investigational combinations. The first stage compared standard 24-week HRZE treatment against 16-week regimens containing novel compounds.

Researchers measured efficacy using the time-to-positivity slope, tracking the rate of change in Mycobacterium tuberculosis growth in positive sputum cultures over 12 weeks. Steeper slopes indicate faster bacterial clearance.

BPMG and BDMT regimens show faster sputum clearance than standard HRZE

The time-to-positivity slope reached 0.129 log10 days per week with the regimen combining ganfeborole, bedaquiline, pretomanid, and moxifloxacin (BPMG). It reached 0.142 log10 days per week with the combination of BTZ-043, bedaquiline, delamanid, and moxifloxacin (BDMT), compared with 0.118 log10 days per week for the standard isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) regimen.

The posterior probability of superiority reached 0.83 for BPMG and 0.99 for BDMT when compared directly against the standard four-drug regimen.

At week 48 of the trial, favorable-outcome status without treatment failure or relapse was observed in 80% of patients in the BPMG group and 93% in the BDMT group, compared with 89% in the standard HRZE group.

Phase II Tuberculosis Trial Regimen Comparisons
Regimen Group Time-to-Positivity Slope (log10 days/wk) Posterior Probability of Superiority Favorable Outcome at Week 48
Standard HRZE 0.118 Reference 89%
BPMG Regimen 0.129 0.83 80%
BDMT Regimen 0.142 0.99 93%

Adaptive platform design enables simultaneous evaluation of multiple TB regimens

The adaptive platform design allowed investigators to evaluate multiple treatment options simultaneously rather than sequentially. “By testing multiple regimens simultaneously within a single trial platform, we were able to evaluate more treatment options in less time than traditional approaches allow,” said Hanif Esmail, professor of infectious diseases at University College London and clinical lead for the trial.

Study authors said that the approach helps prioritize combinations for expensive phase III evaluations.

“Our findings show the potential of large-scale, early-phase clinical trials for evaluating multiple regimens simultaneously with a design that permits the use of early data on treatment failure or relapse to inform selection of regimens for further evaluation,” wrote Nicholas Paton, professor at the National University of Singapore and the London School of Hygiene & Tropical Medicine, and colleagues.

“a potentially very useful approach to prioritizing which regimens should be tested in very long and expensive phase III trials,” Eric Rubin, MD, PhD, of the Harvard T.H. Chan School of Public Health, said. Rubin said that while the trial provides a useful prioritization method, surrogate markers like time to positivity reflect bulk bacterial populations rather than the persistent subpopulations responsible for lengthy cure times.

“You rush a miracle man, you get rotten miracles,” Rubin wrote, quoting the film The Princess Bride to urge caution before accelerating agents into late-stage testing.

Severe adverse events higher in BPMG group than BDMT or standard HRZE

Severe adverse events occurred in 38% of the BPMG group, 28% of the BDMT group, and 24% of the standard HRZE group. Among 118 patients experiencing serious adverse events, 45% showed a decrease in creatinine clearance from baseline, with most experiencing drops exceeding 30%.

Trial limitations cited by authors include an open-label design, small group sizes, and reliance on time-to-positivity as a surrogate endpoint. The study enrolled patients with rifampin-susceptible pulmonary tuberculosis and excluded individuals with HIV.

Frequently Asked Questions About the Trial

What compounds are in the new regimens?

The investigational regimens include novel agents such as ganfeborole, which blocks an enzyme essential for mycobacterial protein synthesis, and BTZ-043, which inhibits cell-wall synthesis, alongside existing drugs like bedaquiline, delamanid, and moxifloxacin.

How many patients and clinical sites participated?

The trial enrolled 401 adults across 14 clinical sites located in South Africa, Tanzania, Uganda, Vietnam, and Moldova.

What are the next steps for the successful regimens?

The four-drug combinations that met selection criteria will advance to the second stage of the phase II trial to determine optimal treatment durations before entering larger phase III trials.

About the author: Health Desk

Health Desk at Archynewsy.